



Announcement No. 23/2008

To OMX Nordic Exchange Copenhagen and the press

Copenhagen, April 30, 2008

### **Exiqon A/S' share capital and total number of voting rights**

Pursuant to Section 6 of executive order no. 1172 of 9 October 2007 about issuers' disclosure obligations, it is hereby announced that Exiqon A/S' entire share capital on 30 April 2008 is DKK 30,139,473, nominal value, divided into shares of DKK 1.00, nominal value, each. Every share of DKK 1.00, nominal value, carries one vote. The total number of voting rights is 30,139,473.

### **For additional information please contact**

CEO Lars Kongsbak, tel. +45 4566 0888 or +45 4090 2101

CFO, Hans Henrik Chrois Christensen tel. +45 4565 0953 or +45 4090 2131

### **About Exiqon**

Exiqon's corporate mission is to combine leading-edge scientific expertise in gene expression with our proprietary LNA™ technology. Exiqon's products, services and scientific staff enable life science researchers to make groundbreaking discoveries. Moreover, Exiqon is addressing the unmet need for a new approach to the diagnosis of cancer. Exiqon's products are based on patented technology (LNA™ or Locked Nucleic Acids) that facilitates very precise and sensitive analysis of nucleic acids. Exiqon aims to expand the existing product offering for research use as well as to develop new proprietary molecular diagnostic products. Exiqon, through a number of recent initiatives, has positioned itself as a significant player in applying miRNA as the key biomarker in cancer diagnostics.

### **Disclaimer**

Forward-looking statements: This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.